Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers

Acta Pharmaceutica

Volumn 57, Issue 3, 2007, Pages 287-300

  Dhumal, Ravindra S ^a   Shimpi, Shamkant L ^a   Paradkar, Anant R ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Amorphous; Carrageenan; Celecoxib; Co precipitate; Compression; PVP; Solid dispersion; Stability; Tableting

Indexed keywords

CARRAGEENAN; CELECOXIB; GELCARIN; GP 379; MACROGOL; POLYMER; POLYVINYL ALCOHOL; POVIDONE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; HYDROGEN BOND; INFRARED SPECTROSCOPY; PRECIPITATION; SPRAY DRYING; TABLET COMPRESSION; VISCOELASTICITY; X RAY POWDER DIFFRACTION;

EID: 34548711868     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10007-007-0023-7     Document Type: Article

References (21)

1. A. R. Paradkar, B. Chauhan, S. Yamamura and A. P. Pawar, Preparation and characterization of glassy celecoxib, Drug Dev. Ind. Pharm. 29 (2003) 739-744; DOI: 10.1081/DDC-120021773.
2. P. Gupta, G. Chawala and A. K. Bansal, Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility, Mol. Pharm. 1 (2004) 406-413; DOI: 10.1021/mp049938f.
3. M. K. Gupta., A. Vanwert and R. H. Bogner, Formation of physically stable amorphous drugs by milling with Neusilin, J. Pharm. Sci. 92 (2003) 536-551; DOI: 10.1002/jps.10308.
4. D. Q. Craig, P. G. Royall, V. L. Kett and M. L. Hopton, The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems, Int. J. Pharm. 179 (1999) 179-207; DOI: 10.1016/S0378-5173(98)00338-X.
5. A. A. Ambike, K. R. Mahadik, A. R. Paradkar, Stability study of amorphous valdecoxib, Int. J. Pharm. 282 (2004) 151-162; DOI: 10.1080/03639040500272025.
6. A. Paradkar, M. Maheshwari, R Kamble, I. Grimsey and P. York, Design and evaluation of celecoxib porous particles using melt sonocrystallization, Pharm. Res. 23 (2005) 1395-1400; DOI: 10.1007/s11095-006-0020-4.
7. D. Law, S. L. Krill, E. A. Schmitt, J. J. Fort, Y. H. Qiu, W. L. Wang and W. R. Porter, Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions, J. Pharm. Sci. 90 (2001) 1015-1025; DOI: 10.1002/jps.1054.
8. H. Suzuki and H. Sunada, Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers, Chem. Pharm. Bull. 46 (1998) 482-487.
9. S. L. Shimpi, B. Chauhan, K. R. Mahadik and A. R. Paradkar, Stabilization and improved in-vivo performance of amorphous etoricoxib using gelucier 50/13, Pharm. Res. 22 (2005) 1727-1734; DOI: 10.1007/s11095-005-6694-1.
10. P. Gupta, V. K. Kakamanu and A. K. Bansal, Stability and solubility of celecoxib-PVP amorphous dispersions: molecular perspective, Pharm. Res. 21 (2004) 1762-1769; DOI:10.1023/B:PHAM.0000045226.42859.b8.
11. P. Gupta, R. Thilagavathi, A. K. Chakraborti and A. K. Bansal, Role of molecular interaction in stability of celecoxib-PVP amorphous systems, Mol. Pharm. 2 (2005) 384-391.
12. J. Akbuga, A. Gursoy and F. Yetimoglu, Preparation and properties of tablets prepared from furosemide-PVP solid dispersion systems, Drug Dev. Ind. Pharm. 14 (1988) 2091-2108.
13. K. R. Morris, U. J. Griesserb, C. J. Eckhardt and J. G. Stowell, Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes, Adv. Drug Deliv. Rev. 48 (2001) 91-114; DOI: 10.1016/S0169-409X(01)00100-4.
14. T. Matsumoto, N. Kaneniwa, S. Higuchi and M. Otsuka, Effects of temperature and pressure during compression on the polymorphic transformation and crushing strength of chlorpropamide tablets, J. Pharm. Pharmacol. 43 (1991) 74-78.
15. V. Andronis and G. Zografi, The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity, Pharm. Res. 15 (1998) 835-842.
16. M. Otsuka, M. Nakanishi and Y. Matsuda. Effects of crystalline form on compression mechanism of phenobarbital polymorphs, Drug Dev. Ind. Pharm. 25 (1999) 205-215.
17. C. Lefebvre, A. M. Guyot-Hermann, M. Draguet-Bruchmans and R. Bouche, Polymorphic transitions of carbamazepine during grinding and compression, Drug Dev. Ind. Pharm. 12 (1986) 1913-1927.
18. H. Chan and E. Doelker, Polymorphic transformation of some drugs under compression, Drug Dev. Ind. Pharm. 11 (1985) 315-332.
19. A. G. Schmidt, S. Wartewig and K. M. Picker, Potential of carrageenan to protect drugs from polymorphic transformation, Eur. J. Pharm. Biopharm. 56 (2003) 101-110; DOI: 10.1016/S0939-6411(03)00037-7.
20. K. M. Picker, »Soft tableting«: A new concept to tablet pressure sensitive materials, Pharm. Dev. Technol. 9 (2004) 107-121; DOI: 10.1081/PDT-120027426.
21. United States Pharmacopoeia 24, National Formulary 19, USP Convention, Rockville 2000.